Dean Lenz, MD
Urology · Bloomington, INNPI 1003912726
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $192 of the $227 with a category attached, or 84.5%. Boston Scientific accounts for 78.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $179 and has fallen 80.4% since, to $35 in 2025. That places this record below the midpoint for urology clinicians in IN, where the typical reported total is $3,350.
Across 5 payments — averaging $45.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$178
- AstraZeneca$35
- Procept Biorobotics Corporation$14
What the payments were for
- Food & beverage$19285%
- Education$3515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $178 |
| AstraZeneca | 1 | $35 |
| Procept Biorobotics Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LithoVue$150
How this compares
$227 in reported general payments places this provider in the 10th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 59 | $51,840 |
| MyrbetriqMirabegron | 13 | $13,777 |
| Finasteride | 627 | $8,480 |
| Tamsulosin Hcl | 674 | $7,926 |
| Solifenacin Succinate | 64 | $2,520 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,955 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 16 | $1,474 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 30 | $1,201 |
| NitrofurantoinNitrofurantoin Macrocrystal | 16 | $1,041 |
| Testosterone Cypionate | 62 | $994 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 108 | $369 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $305 |
| Dutasteride | 23 | $301 |
| Cephalexin | 67 | $298 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $239 |
Paid to pharmacies, not to this prescriber.
Other urology in Bloomington
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Matthew MellonCarmel$159K
- James BailenJeffersonville$143K
- Greg SteinbockJeffersonville$134K
- Eugene ConeGreenwood$114K
- Jason KovacCarmel$112K
- Helen BernieIndianapolis$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.